Table 1.
Dependent Variable |
CORT Treatment | Hatch Date | Hatch Order | Clutch # | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Day | N | Est | SE | P | N | Est | SE | P | N | Est | SE | P | N | Est | SE | P | |
14 | Baseline CORT | 100 | 0.63 | 0.05 | <0.001 | ||||||||||||
BKA | 31 | 0.02 | 0.07 | 0.810 | 31 | 0.00 | 0.0 | 0.030 | 31 | 0.08 | 0.03 | 0.020 | |||||
| |||||||||||||||||
36 | BKA | 116 | 0.03 | 0.04 | 0.500 | 116 | 0.03 | 0.04 | 0.055 | ||||||||
| |||||||||||||||||
60 | Baseline CORT | 98 | 0.07 | 0.09 | 0.420 | ||||||||||||
Stress CORT | 99 | 0.0 | 0.09 | 0.970 | 99 | 0.1 | 0.05 | 0.047 | |||||||||
BKA | 25 | 0.01 | 0.05 | 0.850 | 25 | 0.00 | 0.0 | 0.001 | |||||||||
| |||||||||||||||||
68 | Anti-LPS Ab | 57 | 0.02 | 0.28 | 0.940 | ||||||||||||
| |||||||||||||||||
100 | Baseline Hp | 85 | 0.02 | 0.01 | 0.100 | 85 | 0.02 | 0.01 | <0.001 | ||||||||
12-Hr Hp | 83 | 0.0 | 0.01 | 0.940 | 83 | 0.00 | 0.00 | 0.001 | |||||||||
| |||||||||||||||||
108 | Anti-LPS Ab | 43 | 0.08 | 0.55 | 0.880 | 43 | 0.01 | 0.00 | 0.005 |
CORT dosing elevated circulating CORT concentrations during the treatment period (i.e., day 14) but did not impact subsequent CORT concentrations, either baseline or concentrations produced in response to lipopolysaccharide (LPS) challenge (LPS CORT). Developmental CORT treatment also did not significantly affect immune parameters. BKA=Bacteria killing ability, Anti-LPS Ab=specific antibodies to LPS, Hp=haptoglobin, 12-Hr Hp=haptoglobin concentrations measured 12 hours after LPS challenge. Est is the model estimate (slope of the relationship) between parameters. Significant (p<0.05) effects are bolded.